id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-284841-flhfagp3	Nicol, Thomas	Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech)	2020-06-15		.txt	text/plain	2806	214	58	METHODS: Two automated immunoassays (Abbott SARS-CoV-2 CLIA IgG and Euroimmun Anti-SARS-CoV-2 ELISA IgG/IgA assays) and one lateral flow immunoassay (LFIA NG-Test® IgG-IgM COVID-19) were tested. The aim of the study was to assess the clinical performance of CE marked assays available in Europe to detect SARS-CoV-2 antibodies: two automated immunoassays (Euroimmun and Abbott assays) targeting two different proteins and also one lateral flow immunoassay (NG Biotech). On May, 2020, the French Health Authority (Haute Autorité de Santé) and Infectious Diseases Society of America recommended that patients with symptoms consistent with COVID-19 but having a positive result for SARS-CoV-2 by RT-PCR may be diagnosed by serological tests [22, 23] . Here, we did not observe any significant difference between sensitivity of IgA ELISA and IgM LFIA In conclusion, our study showed equivalent clinical performance for IgG of three immunoassays (ELISA, CLIA and LFIA) >14 days after symptoms onset.	./cache/cord-284841-flhfagp3.txt	./txt/cord-284841-flhfagp3.txt